Compass Therapeutics, Inc.
CMPX
Price:
$1.63
Market Cap:
$224.27M
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachu...[Read more]
Industry
Biotechnology
IPO Date
2021-04-05
Stock Exchange
NASDAQ
Ticker
CMPX
The ROE as of September 2024 (TTM) for Compass Therapeutics, Inc. (CMPX) is -28.67%
According to Compass Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.67%. This represents a change of 297.89% compared to the average of -7.21% of the last 4 quarters.
Compass Therapeutics, Inc. (CMPX) Historical ROE (quarterly & annually)
How has CMPX ROE performed in the past?
The mean historical ROE of Compass Therapeutics, Inc. over the last ten years is -17.87%. The current -28.67% ROE has changed 60.50% with respect to the historical average. Over the past ten years (40 quarters), CMPX's ROE was at its highest in in the June 2019 quarter at 10.74%. The ROE was at its lowest in in the June 2021 quarter at -193.26%.
Average
-17.87%
Median
-24.43%
Minimum
-73.85%
Maximum
45.16%
Compass Therapeutics, Inc. (CMPX) ROE by Quarter and Year
Discovering the peaks and valleys of Compass Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 41.22%
Maximum Annual ROE = 45.16%
Minimum Annual Increase = -352.10%
Minimum Annual ROE = -73.85%
| Year | ROE | Change |
|---|---|---|
| 2023 | -28.61% | 41.22% |
| 2022 | -20.26% | -65.63% |
| 2021 | -58.93% | -20.20% |
| 2020 | -73.85% | -352.10% |
| 2020 | 29.29% | -35.14% |
Compass Therapeutics, Inc. (CMPX) Average ROE
How has CMPX ROE performed in the past?
The current ROE of Compass Therapeutics, Inc. (CMPX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-35.93%
5-year avg
-30.47%
10-year avg
-17.87%
Compass Therapeutics, Inc. (CMPX) ROE vs. Peers
How is CMPX’s ROE compared to its peers?
Compass Therapeutics, Inc.’s ROE is greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than NewAmsterdam Pharma Company N.V. (-81.09%), less than Inventiva S.A. (550.46%), greater than Cullinan Oncology, Inc. (-28.37%), greater than PepGen Inc. (-62.74%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Vigil Neuroscience, Inc. (-76.02%), greater than PureTech Health plc (-29.01%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Enliven Therapeutics, Inc. (-29.31%), greater than MoonLake Immunotherapeutics (-11.05%), greater than Structure Therapeutics Inc. (-20.15%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%),
| Company | ROE | Market cap |
|---|---|---|
| -20.53% | $2.94B | |
| -255.67% | $1.10B | |
| -86.28% | $332.04M | |
| -44.73% | $2.09B | |
| -100.91% | $3.02M | |
| -70.40% | $365.17M | |
| -81.09% | $1.44B | |
| 550.46% | $122.31M | |
| -28.37% | $998.94M | |
| -62.74% | $301.78M | |
| -27.13% | $1.22B | |
| -76.02% | $137.58M | |
| -29.01% | $464.80M | |
| -83.65% | $55.14M | |
| -29.31% | $1.03B | |
| -11.05% | $3.34B | |
| -20.15% | $2.19B | |
| -52.15% | $757.00M | |
| -152.26% | $124.97M | |
| -143.74% | $17.92M | |
| -68.82% | $55.48M | |
| -117.33% | $206.12M |
Build a custom stock screener for Compass Therapeutics, Inc. (CMPX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Compass Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Compass Therapeutics, Inc. (CMPX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Compass Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Compass Therapeutics, Inc.'s ROE?
How is the ROE calculated for Compass Therapeutics, Inc. (CMPX)?
What is the highest ROE for Compass Therapeutics, Inc. (CMPX)?
What is the 3-year average ROE for Compass Therapeutics, Inc. (CMPX)?
What is the 5-year average ROE for Compass Therapeutics, Inc. (CMPX)?
How does the current ROE for Compass Therapeutics, Inc. (CMPX) compare to its historical average?